[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Ace Surgical Supply Co., Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":183},{"warningLetters":4,"total":182},[5,32,54,80,100,123,143,165],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":27,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":19,"reference_number":19,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},1645,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-01-30T14:20:00Z\">01\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-01-08T05:00:00Z\">01\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgrace-supply-inc-668552-01082024\">Grace Supply Inc.\u003C\u002Fa>"," Division of Southwest Imports","Foreign Supplier Verification Program (FSVP)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Varghese Kurian\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Grace Supply Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13740 Pike Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Missouri City\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77489-1015\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 8, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 668552\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kurian,\u003C\u002Fp>\n\n\u003Cp>From August 16 through September 6, 2023, the Food and Drug Administration (FDA) conducted a remote Foreign Supplier Verification Program (FSVP) inspection of Grace Supply Inc., located at 13740 Pike Rd., Missouri City, TX 77489-1015. We also conducted an inspection from February 13 through 16, 2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links on FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import except for banana chips imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with Form FDA 483a, FSVP Observations. During the inspection, you informed our investigator that you would begin working to correct the deficiencies and stated you needed between six months to one year due to the high number of imported products and foreign suppliers. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your planned or completed corrective actions. Additionally, we have not received your response to the Form FDA 483a issued on September 16, 2023.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any foods that you import, except for the following foods:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Extra hot snack mix imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Shredded frozen coconut imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Banana chips imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>While you provided FSVP documents for extra hot snack mix imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and shredded frozen coconut from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, these documents do not meet the FSVP requirements, as discussed below.\u003C\u002Fp>\n\n\u003Cp>2. Your hazard analysis for the shredded frozen coconut from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, did not identify and evaluate coconut as a potential chemical hazard (food allergen) to determine whether the hazard requires a control per 21 CFR 1.504(a). A hazard analysis must identify known or reasonably foreseeable hazards for each type of food you import to determine whether there are any hazards requiring a control (21 CFR 1.504(a)). The analysis of the known or reasonably foreseeable hazards in each food must include biological hazards, chemical hazards (including pesticide residues), and physical hazards (21 CFR 1.504(b)(1)). Specifically, coconut is a tree nut and is recognized by FDA as a food allergen. Your hazard analysis for shredded frozen coconut and the hazard analysis provided by your foreign supplier did not identify and evaluate coconut as a potential chemical hazard.\u003C\u002Fp>\n\n\u003Cp>3. You did not meet the requirements to conduct and document (or obtain documentation of) one or more of the supplier verification activities listed in 21 CFR 1.506(e)(1)(i) through (iv) for each foreign supplier before importing the food and periodically thereafter, as required by 21 CFR 1.506(e)(1). Your FSVP for the extra hot snack mix imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, documented that you determined “a combination of sampling and testing and review of relevant food safety records is the appropriate verification activity” with a frequency of “quarterly until a history is established and annually thereafter.” However, you did not conduct and document (or obtain documentation of) one or more such supplier verification activities for your foreign supplier. Your FSVP included a copy of a self-assessment audit report for the extra hot snack mix imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, however the audit was conducted at your supplier’s parent company, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, not your supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, you did not document or provide records of any sampling and testing results. Therefore, you did not conduct and document or obtain documentation of one or more supplier verification activities before importing your extra hot snack mix imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> into the United States, as required per 21 CFR 1.506(e)(1).\u003C\u002Fp>\n\n\u003Cp>4. Your supplier verification activities did not provide adequate assurance that the hazards requiring a control in the foods you import have been significantly minimized or prevented, as required by 21 CFR 1.506(c). Specifically, you determined that for your shredded frozen coconut from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, there is a hazard, specifically \u003Cem>Salmonella\u003C\u002Fem>, that will be controlled by the foreign supplier. \u003Cem>Salmonella\u003C\u002Fem> is a hazard that results in serious adverse health consequences or death to humans or animals (SAHCODHA).\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In accordance with 21 CFR 1.506(d)(2), when a hazard in a food will be controlled by the foreign supplier and is one for which there is a reasonable probability that exposure to the hazard will result in serious adverse health consequences or death to humans or animals, you must conduct or obtain documentation of an onsite audit of the foreign supplier before initially importing the food and at least annually thereafter, unless you make an adequate written determination that, instead of such initial and annual onsite auditing, other supplier verification activities listed under 21 CFR 1.506(d)(1)(ii) and\u002For less frequent onsite auditing are appropriate to provide adequate assurances that the foreign supplier is producing the food in accordance with 21 CFR 1.506(c), based on the determination made under § 1.505.\u003C\u002Fp>\n\n\u003Cp>Based on a review of your FSVP documents for shredded frozen coconut from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you did not conduct and document or obtain documentation of an onsite audit of the foreign supplier at least annually after importing the food into the United States. Although you provided documentation of an FDA on-site inspection conducted January 31, 2019, of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, it was not conducted before initially importing the food and at least annually thereafter.\u003C\u002Fp>\n\n\u003Cp>Furthermore, your FSVP did not describe adequate written determination that other supplier verification activities are appropriate to provide adequate assurances that the foreign supplier is producing the food in accordance with 21 CFR 1.506(c). In your FSVP section “8. FOREIGN SUPPLIER VERIFICATION ACTIVITIES” you have determined verification activities to be a combination of sampling and testing and review of relevant food safety. However, a review of your foreign supplier’s hazard analysis has shown that there are inadequate controls by your foreign supplier for the \u003Cem>Salmonella\u003C\u002Fem> hazard. There is no kill step in the manufacturing process for shredded frozen coconut to eliminate potential pathogens that may exist in the raw material (whole coconut). Further there are no records of the supplier having a supply-chain program in place to control the hazard (e.g. requiring a COA of incoming raw material) or a process control to eliminate pathogens. Accordingly, finished product testing every \u003Cstrong>(b)(4)\u003C\u002Fstrong> months as described in your FSVP is not an appropriate verification activity for a serious hazard (\u003Cem>Salmonella\u003C\u002Fem>), as required by 21 CFR 1.506(d)(2). Therefore, your FSVP does not describe adequate written determination that other supplier verification activities instead of annual onsite auditing, are appropriate, and does not provide adequate assurance that the Salmonella hazard requiring a control in the shredded frozen coconut you import has been significantly minimized or prevented.\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import which appear to be in violation of section 805. We may place these foods you import into the United States on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>In addition to the above violations, we also have the following comments:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>If you are a importing food from a small foreign supplier as specified in 21 CFR 1.512(a)(2) and you choose to comply with the requirements in this section, you must obtain written assurance that your small foreign supplier meets the criteria before first approving the supplier for an applicable calendar year and thereafter on an annual basis by December 31 of each calendar year, per 21 CFR 1.512(b)(1)(ii). The written declaration you provided for your small foreign supplier of banana chips, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, stated that they should be considered a small foreign supplier, however it was not dated, thus it is not clear if you obtained the written assurance prior to importing from your foreign supplier. Furthermore, it is not clear whether your supplier was approved as a small foreign supplier or per standard requirements. For example, your FSVP for banana chips imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> included documents that are not required for a small foreign supplier, such as additional food safety records including a hazard analysis, completed sections for hazard analysis review and assessment, evaluation of foreign supplier’s performance, and foreign supplier verification activities.\u003C\u002Fli>\n\t\u003Cli>You must sign and date an FSVP record upon initial completion, as required by 21 CFR 1.512(b)(5)(i)(B) and 21 CFR 1.510(a)(2), respectively. However, we noted that for each section that designated a date and signature in your FSVPs provided for the banana chips from \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the extra hot snack mix from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, other than the section for supplier approval, the date and signature were missing.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Ernesto Barba, Compliance Officer, Division of Southwest Imports, 9725 Via de la Amistad, Ste 200, San Diego, CA 92154. If you have any questions regarding this letter, you may contact Compliance Officer Ernesto Barba via email at Ernesto.Barba@fda.hhs.gov. Please reference CMS # 668552 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Todd Cato\u003Cbr>\nDirector\u003Cbr>\nDivision of Southwest Imports\u003Cbr>\nOne Main Place\u003Cbr>\n1201 Main Street, Suite 7200\u003Cbr>\nDallas, TX 75202\u003Cbr>\n\u003Cbr>\nCc:\u003Cbr>\nGrace Suppy, Inc.\u003Cbr>\n13740 Pike Rd\u003Cbr>\nMissouri City, TX 77489-1015\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Cem>See\u003C\u002Fem> \u003Cstrong>Guidance for Industry and FDA Staff: Questions and Answers Regarding Mandatory Food Recalls&nbsp;\u003C\u002Fstrong>https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-and-fda-staff-questions-and-answers-regarding-mandatory-food-recalls (listing Salmonella in ready-to eat food as an example of food that represents a SAHCODHA risk).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nVarghese Kurian\n\nRecipient Title\n\nPresident\n\nGrace Supply Inc.\n\n13740 Pike Rd\n\nMissouri City, TX 77489-1015\n\nUnited States\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nJanuary 8, 2024\n\nWARNING LETTER\n\nRe: CMS # 668552\n\nDear Mr. Kurian,\n\nFrom August 16 through September 6, 2023, the Food and Drug Administration (FDA) conducted a remote Foreign Supplier Verification Program (FSVP) inspection of Grace Supply Inc., located at 13740 Pike Rd., Missouri City, TX 77489-1015. We also conducted an inspection from February 13 through 16, 2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links on FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import except for banana chips imported from (b)(4), located in (b)(4). Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with Form FDA 483a, FSVP Observations. During the inspection, you informed our investigator that you would begin working to correct the deficiencies and stated you needed between six months to one year due to the high number of imported products and foreign suppliers. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your planned or completed corrective actions. Additionally, we have not received your response to the Form FDA 483a issued on September 16, 2023.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any foods that you import, except for the following foods:\n\nExtra hot snack mix imported from (b)(4), (b)(4)\n\nShredded frozen coconut imported from (b)(4), (b)(4)\n\nBanana chips imported from (b)(4) and (b)(4), (b)(4)\n\nWhile you provided FSVP documents for extra hot snack mix imported from (b)(4), located in (b)(4) and shredded frozen coconut from (b)(4), located in (b)(4), these documents do not meet the FSVP requirements, as discussed below.\n\n2. Your hazard analysis for the shredded frozen coconut from (b)(4), located in (b)(4), did not identify and evaluate coconut as a potential chemical hazard (food allergen) to determine whether the hazard requires a control per 21 CFR 1.504(a). A hazard analysis must identify known or reasonably foreseeable hazards for each type of food you import to determine whether there are any hazards requiring a control (21 CFR 1.504(a)). The analysis of the known or reasonably foreseeable hazards in each food must include biological hazards, chemical hazards (including pesticide residues), and physical hazards (21 CFR 1.504(b)(1)). Specifically, coconut is a tree nut and is recognized by FDA as a food allergen. Your hazard analysis for shredded frozen coconut and the hazard analysis provided by your foreign supplier did not identify and evaluate coconut as a potential chemical hazard.\n\n3. You did not meet the requirements to conduct and document (or obtain documentation of) one or more of the supplier verification activities listed in 21 CFR 1.506(e)(1)(i) through (iv) for each foreign supplier before importing the food and periodically thereafter, as required by 21 CFR 1.506(e)(1). Your FSVP for the extra hot snack mix imported from (b)(4), located in (b)(4), documented that you determined “a combination of sampling and testing and review of relevant food safety records is the appropriate verification activity” with a frequency of “quarterly until a history is established and annually thereafter.” However, you did not conduct and document (or obtain documentation of) one or more such supplier verification activities for your foreign supplier. Your FSVP included a copy of a self-assessment audit report for the extra hot snack mix imported from (b)(4), however the audit was conducted at your supplier’s parent company, (b)(4), not your supplier (b)(4). Further, you did not document or provide records of any sampling and testing results. Therefore, you did not conduct and document or obtain documentation of one or more supplier verification activities before importing your extra hot snack mix imported from (b)(4) into the United States, as required per 21 CFR 1.506(e)(1).\n\n4. Your supplier verification activities did not provide adequate assurance that the hazards requiring a control in the foods you import have been significantly minimized or prevented, as required by 21 CFR 1.506(c). Specifically, you determined that for your shredded frozen coconut from (b)(4), there is a hazard, specifically Salmonella, that will be controlled by the foreign supplier. Salmonella is a hazard that results in serious adverse health consequences or death to humans or animals (SAHCODHA).1 In accordance with 21 CFR 1.506(d)(2), when a hazard in a food will be controlled by the foreign supplier and is one for which there is a reasonable probability that exposure to the hazard will result in serious adverse health consequences or death to humans or animals, you must conduct or obtain documentation of an onsite audit of the foreign supplier before initially importing the food and at least annually thereafter, unless you make an adequate written determination that, instead of such initial and annual onsite auditing, other supplier verification activities listed under 21 CFR 1.506(d)(1)(ii) and\u002For less frequent onsite auditing are appropriate to provide adequate assurances that the foreign supplier is producing the food in accordance with 21 CFR 1.506(c), based on the determination made under § 1.505.\n\nBased on a review of your FSVP documents for shredded frozen coconut from (b)(4), you did not conduct and document or obtain documentation of an onsite audit of the foreign supplier at least annually after importing the food into the United States. Although you provided documentation of an FDA on-site inspection conducted January 31, 2019, of (b)(4), located in (b)(4), it was not conducted before initially importing the food and at least annually thereafter.\n\nFurthermore, your FSVP did not describe adequate written determination that other supplier verification activities are appropriate to provide adequate assurances that the foreign supplier is producing the food in accordance with 21 CFR 1.506(c). In your FSVP section “8. FOREIGN SUPPLIER VERIFICATION ACTIVITIES” you have determined verification activities to be a combination of sampling and testing and review of relevant food safety. However, a review of your foreign supplier’s hazard analysis has shown that there are inadequate controls by your foreign supplier for the Salmonella hazard. There is no kill step in the manufacturing process for shredded frozen coconut to eliminate potential pathogens that may exist in the raw material (whole coconut). Further there are no records of the supplier having a supply-chain program in place to control the hazard (e.g. requiring a COA of incoming raw material) or a process control to eliminate pathogens. Accordingly, finished product testing every (b)(4) months as described in your FSVP is not an appropriate verification activity for a serious hazard (Salmonella), as required by 21 CFR 1.506(d)(2). Therefore, your FSVP does not describe adequate written determination that other supplier verification activities instead of annual onsite auditing, are appropriate, and does not provide adequate assurance that the Salmonella hazard requiring a control in the shredded frozen coconut you import has been significantly minimized or prevented.\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import which appear to be in violation of section 805. We may place these foods you import into the United States on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nIn addition to the above violations, we also have the following comments:\n\nIf you are a importing food from a small foreign supplier as specified in 21 CFR 1.512(a)(2) and you choose to comply with the requirements in this section, you must obtain written assurance that your small foreign supplier meets the criteria before first approving the supplier for an applicable calendar year and thereafter on an annual basis by December 31 of each calendar year, per 21 CFR 1.512(b)(1)(ii). The written declaration you provided for your small foreign supplier of banana chips, (b)(4), located in (b)(4), stated that they should be considered a small foreign supplier, however it was not dated, thus it is not clear if you obtained the written assurance prior to importing from your foreign supplier. Furthermore, it is not clear whether your supplier was approved as a small foreign supplier or per standard requirements. For example, your FSVP for banana chips imported from (b)(4) included documents that are not required for a small foreign supplier, such as additional food safety records including a hazard analysis, completed sections for hazard analysis review and assessment, evaluation of foreign supplier’s performance, and foreign supplier verification activities.\n\nYou must sign and date an FSVP record upon initial completion, as required by 21 CFR 1.512(b)(5)(i)(B) and 21 CFR 1.510(a)(2), respectively. However, we noted that for each section that designated a date and signature in your FSVPs provided for the banana chips from (b)(4) and (b)(4), and the extra hot snack mix from (b)(4), other than the section for supplier approval, the date and signature were missing.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to the Food and Drug Administration, Attention: Ernesto Barba, Compliance Officer, Division of Southwest Imports, 9725 Via de la Amistad, Ste 200, San Diego, CA 92154. If you have any questions regarding this letter, you may contact Compliance Officer Ernesto Barba via email at Ernesto.Barba@fda.hhs.gov. Please reference CMS # 668552 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nDirector\n\nDivision of Southwest Imports\n\nOne Main Place\n\n1201 Main Street, Suite 7200\n\nDallas, TX 75202\n\nCc:\n\nGrace Suppy, Inc.\n\n13740 Pike Rd\n\nMissouri City, TX 77489-1015\n\n_____________________\n\n1 See Guidance for Industry and FDA Staff: Questions and Answers Regarding Mandatory Food Recalls https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-and-fda-staff-questions-and-answers-regarding-mandatory-food-recalls (listing Salmonella in ready-to eat food as an example of food that represents a SAHCODHA risk).","Grace Supply Inc.","grace-supply-inc-668552-01082024","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgrace-supply-inc-668552-01082024","2026-10-26T08:08:48.866498+00:00","Warning Letter","Issued","2024-01-30","668552","Food & Beverages","Division of Southwest Imports","Varghese Kurian","2026-08-20T00:21:04.844+00:00","Via Express Delivery","2024-01-08",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},746,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2025-07-29T04:00:00Z\">07\u002F29\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-21T04:00:00Z\">07\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonkos-surgical-inc-712573-07212025\">Onkos Surgical, Inc. \u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Patrick J. Treacy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Onkos Surgical, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>77 E Halsey Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Parsippany\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ptreacy@onkossurgical.com\"> ptreacy@onkossurgical.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 712573\u003C\u002Fp>\u003Cp>July 21, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Patrick J. Treacy:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Parsippany, NJ from February 4, 2025 through April 4, 2025, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer of the ELEOS Limb Salvage System indicated for use in total hip and knee arthroplasty for reduction or relief of pain and\u002For improved hip function in skeletally mature patients with select conditions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Len Tokish, Vice President of Quality Assurance and Regulatory Affairs dated May 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to adequately implement the “Approved Supplier List” section of your “Supplier, Purchasing and Inspection Controls” procedure (SOP-013; Rev. 0-6; Effective: 4\u002F25\u002F16 - 2\u002F3\u002F25) which requires that you “\u003Cem>ensure compliance to ISO 13485\u003C\u002Fem>” for your Tier 1 suppliers as a “method of control” over approved suppliers. For example, you did not ensure compliance to the process validation requirements (clause 7.5.6) of ISO 13485 (Medical Devices – Quality Management Systems – Requirements for regulatory purposes) for the following three (3) Tier 1 suppliers in that you failed to adequately assess and\u002For document an assessment of the acceptability of their cleaning validations meant to demonstrate that in-process or final cleaning of your ELEOS Implant Devices and Instruments consistently meet your specifications for cleanliness:\u003C\u002Fp>\u003Cp>a. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – Tier \u003Cstrong>(b)(4)\u003C\u002Fstrong> Final Cleaner of ELEOS Implant Devices\u003C\u002Fp>\u003Cp>i. You approved the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validation test report TR-2771D-01 (Rev. 1-2; Approved: 1\u002F24\u002F19 and 9\u002F10\u002F21) from this supplier despite it failing to define the maximum allowable devices per gallon per run, as required by section 9.2 of the corresponding test protocol TP-2771D-01 (Rev. 2; Approved: 9\u002F10\u002F21) which states “***\u003Cem>The main cleaning parameters that can impact the efficacy of the cleaning process include ***Quantity of parts\u003C\u002Fem> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)***.”\u003C\u002Fp>\u003Cp>Similarly, you approved \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validation test report TR-2771E-01 (Rev. 1; Approved: 3\u002F18\u002F19) from this supplier despite it failing to document the maximum allowable quantity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> per run, as required by sections 9.3, 9.4, and 9.5 of the corresponding test protocol TP-2771E-01 (Rev. 1; Approved: 8\u002F28\u002F18) which state “***\u003Cem>To validate the cleaning process, parts shall be cleaned using\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>over\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>runs***To create a\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>batch of product***Clean what is expected to be a\u003C\u002Fem> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” load in \u003Cstrong>(b)(4)\u003C\u002Fstrong>***\u003Cem>A cleaning process should not alter the appearance of parts or cause damage. If applicable, appropriate fixtures to hold the components during cleaning should be included in the study and used in routine production\u003C\u002Fem>***.”\u003C\u002Fp>\u003Cp>ii. You failed to adequately assess differences in product design and geometrical configurations of candidate devices for the adoption into device families of existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validations conducted by this supplier because you did not accurately answer guiding questions contained in your “\u003Cem>Assessment of Product Change or New Product Adoption for Cleaning Processes\u003C\u002Fem>” reports. For example:\u003C\u002Fp>\u003Cp> The AC-2772-01 (Rev. 01; Effective: 7\u002F25\u002F19) and AC-277D-01 (Rev. 2; Effective: 2\u002F26\u002F21) reports show that you failed to document rationale to support your answers of “no” to the question posed in section 2 – “\u003Cem>In relation to the existing product, does the candidate product have a similar or less complex design?\u003C\u002Fem>” – despite the candidate devices having 4 grooves, a drive, or a male thread compared to the worst-case and comparison devices, which have none of these features.\u003C\u002Fp>\u003Cp> The AC-2772-02 report (Rev. 1; Effective: 3\u002F23\u002F20) shows that you incorrectly answered “no” to the question posed in section 2 – “\u003Cem>In relation to the existing product, does the candidate product have fewer\u002Fsmaller or equivalent cannulated portions or lumens?\u003C\u002Fem>” – when you compared the candidate device (segmental proximal femur, PF-2000L-02M), which has 7 cannulated holes, to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> device (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) and comparison devices (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), which contain no holes.\u003C\u002Fp>\u003Cp>b. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – Tier 1 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Implant Devices\u003C\u002Fp>\u003Cp>Although requested during the inspection, your Vice President of Quality Affairs and Regulatory Affairs was unable to provide documentation that you assessed the adequacy of the cleaning validations conducted in 2009 by this supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In reviewing the “Process Validation of***\u003Cstrong>(b)(4)\u003C\u002Fstrong> Clean Line” Operational Qualification (OQ) (E118-2116; Rev. 1; Approved: 1\u002F9\u002F09) and Performance Qualification (PQ) (E118-2116; Rev. 1; Approved: 2\u002F3\u002F09), the following deficiencies were observed:\u003C\u002Fp>\u003Cp>i. The rationale in the PQ report to accept deviations from the nominal operating range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F) because OQ data showed that the process monitoring, total organic carbon (TOC), and gravimetric produced acceptable results at worst-case conditions for temperatures as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F and control charts indicated a lower control limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (Deviation 3) does not take into account the vast differences in sample sizes (\u003Cstrong>(b)(4)\u003C\u002Fstrong> vs. \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and acceptance criterion (Ppk \u003Cstrong>(b)(4)\u003C\u002Fstrong> vs. Ppk \u003Cstrong>(b)(4)\u003C\u002Fstrong>) between PQ and OQ for the same tests (TOC and gravimetric analysis) such that passing results for parameters established during OQ are not transferrable to PQ.\u003C\u002Fp>\u003Cp>ii. This supplier failed to document rationale in the OQ and PQ reports for why it was acceptable to convert all negative values measured for the corrected “\u003Cem>mass recovered from gravimetric\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> and corrected “\u003Cem>mass recovered from\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> to 0.00 mg in the “\u003Cem>Gravimetric Extraction Summary\u003C\u002Fem>” table during gravimetric testing, thereby passing the acceptance criteria of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002Fcm\u003Csup>2\u003C\u002Fsup> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). For example, during OQ, an \u003Cstrong>(b)(4)\u003C\u002Fstrong> value as high as -1.59 mg for “Hip – 4” was converted to 0.00 mg without an explanation that accounts for the possibility of testing errors, inadequate test methodology (e.g., lack of sensitivity of testing methods), and uncalibrated state of measuring equipment.\u003C\u002Fp>\u003Cp>c. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Implant Devices &amp; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Instruments\u003C\u002Fp>\u003Cp>You approved the adoption of new products into this supplier’s existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validations titled “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Equipment &amp; Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) and “Zenith Final Ultrasonic Cleaning Equipment &amp; Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) per your Cleaning, Assembly, Packaging and Sterility (CAPS) Checklists for Project # 16-001 (Approved 10\u002F2\u002F24) and Project # 16-003 (Approved 4\u002F19\u002F24) referencing memo “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning” (2\u002F14\u002F19) and results of a 3rd party audit conducted 2\u002F23\u002F18 despite the following deficiencies:\u003C\u002Fp>\u003Cp>i. The OQ and PQ protocols failed to require documentation of the load configurations for all work orders in that the Vice President of Quality Affairs and Regulatory Affairs was not able to determine if devices were put in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> or broken up into \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>ii. The PQ protocol failed to include documentation of valid statistical rationale for cytotoxicity, endotoxin, and\u002For particulate testing. For example, the quantity tested per work order (66672, 66921, 66922) for cytotoxicity and endotoxin was \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> respectively and the quantity tested per work order (66675, 66919, 66920) for cytotoxicity, endotoxin, and particulate was \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The immediate correction is to impose heightened controls at each supplier commensurate with risk until new worst-case cleaning validations can be completed that addresses each of the observed deficiencies for \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 1\u002F15\u002F26, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (target date not provided), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 3\u002F1\u002F26 at the latest.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an assessment of worst-case part justification by family was completed to establish new limits placed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You plan to add this new loading criteria to the final DHR review by 7\u002F15\u002F25. In addition, you plan to require an update to \u003Cstrong>(b)(4)\u003C\u002Fstrong> internal procedure to include predicate cleaning validation review by 7\u002F15\u002F25. Based on the results of the new cleaning validation, you plan to revise top level procedures by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an assessment of worst-case part justification was conducted and monitoring was put in place to control product release by assessing endotoxicity and cytotoxicity on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis. In addition, you plan to require an update to this supplier’s internal procedures to improve notification of triggers to their customers by 7\u002F1\u002F25.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to conduct an assessment for worst-case part challenge per part family by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For all instruments, interim clean line controls were implemented to require shipment of instruments to your firm and analyses of those instruments, which includes worst-case part and part family assessments prior to adoption into your clean-line part family. All parts successfully assessed will then be cleaned using your validated clean line prior to release for commercial distribution. All implants will continue to be shipped to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning and will fall under controls established for therein.\u003C\u002Fp>\u003Cp>Corrective actions include updating your supplier control and design control procedures to establish minimum requirements for cleaning validations of implants and instruments, including defining key product attributes to consider when forming product families and what considerations trigger a new worst-case within a product family or new product cleaning family; creation of a procedure for part families and worst-case parts per family which defines and evaluates implant and instrument cleaning families to facilitate consistent assessment of device cleaning families across products; determination and justification of minimum sample size and attributes (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) for validations; development of a cleaning validation checklist and modification of a supplier audit checklist that captures the aforementioned worst-case part determination, sample sizes, and minimum attributes that will be used during supplier assessment as part of design transfer and new supplier onboarding, manufacturing transfer, and supplier audit; and periodic review of validations on a scheduled interval against new standards and requirements by 6\u002F15\u002F25.\u003C\u002Fp>\u003Cp>However, no target date was provided for the new cleaning validation planned for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, please provide a response regarding how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement your Post Market Surveillance procedure (QP-18-004; Rev. 3; Effective: 6\u002F30\u002F22) which requires opening a CAPA when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis of infection complaints “***\u003Cem>is more than\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>above the literature rate or\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>are above the literature rate\u003C\u002Fem>***” for a given procedure type. For example, you did not initiate CAPAs when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis for infection complaints exceeded the rates of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for the distal femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong>); \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for proximal femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>); and \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for total femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) established in the journal article by Henderson et. al “\u003Cem>Failure Mode Classification for Tumor Endoprostheses: Retrospective Review of Five Institutions and a Literature Review\u003C\u002Fem>” (Journal Bone and Joint Surgery 2011) by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. Under CAPA 24-011 which was initiated on 9\u002F11\u002F24 to create a more robust methodology for trending and analyzing infection related complaints, you conducted a revised retrospective assessment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> infection rates from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> (TM-25-0002; Rev. B; Approved 5\u002F14\u002F25) based on additional literature data to support updated baseline infection rates by procedure type. As a part of the corrective action, you plan to create new work instructions with requirements to perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> trend reporting for infections and \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> trend reports for all other postmarket surveillance key performance indicators (KPIs); revise management review presentation slides and quality planning, postmarket surveillance, complaint handling, and CAPA procedures; and provide training on the new procedures. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to adequately establish and maintain procedures for validating the device design with regards to risk analysis, as required by 21 CFR 820.30(g).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 5.9 of your “Risk Management Process” procedure (SOP-008; Rev. 4-5; Effective: 3\u002F22\u002F23 - 1\u002F17\u002F25) which requires postmarket re-evaluation of risk management for a medical device as well as monitoring of postmarket information “***\u003Cem>for assurance that no unacceptable or previously unrecognized failure modes occur. In the event of such an occurrence the potential that the residual risk or its acceptability has changed and the impact on the previously implemented risk control measures shall be evaluated\u003C\u002Fem>***.” For example, you failed to utilize the real rate of occurrence for loosening in complaints PCR 11272023-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), PCR 05132024-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), and PCR 10172024-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) calculated at 3.27%, 0.149%, and 3.1%, respectively, to evaluate the need to update the occurrence rating in the corresponding ELEOS Stem Implant Risk Table (Project # 16-001\u002F16-003; Rev. E; Approved: 4\u002F1\u002F19), which remains unchanged at \u003Cstrong>(b)(4)\u003C\u002Fstrong>% through \u003Cstrong>(b)(4)\u003C\u002Fstrong>% since April 1, 2019.\u003C\u002Fp>\u003Cp>An update to the postmarket rate of occurrence changes the failure mode from an acceptable risk to a conditionally acceptable risk, thereby requiring an evaluation for the need for additional risk controls and assessment for the acceptability of the residual risk as required under sections 5.6 and 5.7 of SOP-008.\u003C\u002Fp>\u003Cp>The adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. The immediate correction is to evaluate literature, sources, historical data, and\u002For engineering estimates against postmarket data and update the occurrence rates for the hazardous situations associated with the ELEOS Limb Salvage system by \u003Cstrong>(b)(4)\u003C\u002Fstrong> followed by a revision of the corresponding risk tables by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As a part of the corrective action, you plan to revise SOP-008 to ensure that the methods used to create and maintain risk assessment tables are well-defined and create work instructions for conducting risk assessments utilizing postmarket information by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to establish and maintain procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics, as required by 21 CFR 820.250(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 1.1 of your “Sample Size and Statistical Techniques” procedure (SOP-014; Rev. 2-4; Effective: 8\u002F16\u002F18 - 3\u002F22\u002F23) which “***\u003Cem>identifies valid statistical techniques that are used to establish, control and verify the acceptability of process capability and product characteristics***” pertaining to “***inspections and other analyses of objective data\u003C\u002Fem>***” of ELEOS Implant Devices received from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. during incoming inspections. For example, your Vice President of Quality Affairs and Regulatory Affairs acknowledged that the sampling plans of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampled incoming device history records (DHRs) from this supplier were not traceable to a documented valid statistical rationale.\u003C\u002Fp>\u003Cp>a. You reviewed and approved incoming DHRs for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 11\u002F2\u002F20 and 11\u002F29\u002F21 where a sampling plan of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was used to inspect critical features during in-process inspections for which there is no documented rationale for use of this sampling plan. For example, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Tibial Baseplate Component, Size 4 (Part # TB-2204E-01M) Implant Devices, the line profile (curve) for \u003Cstrong>(b)(4)\u003C\u002Fstrong> each were inspected against a specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Similarly, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Collar, 28 Diameter, Round, Porous, HA Treated (Part # HB-2800R-03M) Implant Devices, the diameter for \u003Cstrong>(b)(4)\u003C\u002Fstrong> each was inspected against a specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>b. You reviewed and approved incoming DHRs (Lot #: \u003Cstrong>(b)(4)\u003C\u002Fstrong>) where sampling plans utilized an AQL (acceptable quality limit) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> to inspect features during in-process and final inspections for which there are no documented rationales for use of these sampling plans. For example, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Segmental Proximal Femur, Plasma Spray, Left 98 MM (Part # PF-2000L-02M) Implant Devices, the dimensional specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was inspected at an AQL level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> during final inspection on 1\u002F23\u002F24.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The immediate corrections are to use a checklist to reassess and document rationales for acceptability of the existing AQLs selected for all contract manufactured ELEOS part families from 1\u002F1\u002F21 to 4\u002F1\u002F25 and share the rationales with the contract manufacturers by 11\u002F21\u002F25 and update SCAR 25-01 to require the contract manufacturer to include documented evidence for all inspected dimensions and associated AQL quantities by 5\u002F14\u002F25. As a part of the corrective actions, you plan to update SOP-014 and WI-013-31 (Incoming Inspection Process) to require review of incoming inspection results, consolidation of sampling procedures, set up traceable valid statistical rationales, and confirm AQLs by 7\u002F6\u002F25; update SOP-007 (Design Control) and various design transfer, manufacturing transfer, supplier, and incoming inspection checklists to include instructions for the acceptance of a supplier’s sampling procedure with confirmation of conformance to those procedures during incoming inspection of supplier DHRs by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and develop \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection requirement checklists for all suppliers with a sampling procedure traceable to a valid statistical rationale based on \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 7\u002F18\u002F25. However, these corrections and\u002For corrective actions only address the need to have a statistically valid rationale for the use of sampling plans which follow AQL and not sampling plans which utilize inspections of select critical features for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices. Therefore, please provide a response on how you plan to address the above deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s ELEOS Limb Salvage System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to submit a medical device Report of Correction or Removal for an action initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR Part 806.10. For example:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>a. Your firm conducted a removal of numerous part numbers and lot numbers of your ELEOS Limb Salvage System due to sterile packaging separation and damaged trays, which can result in extended surgery time or potential patient infection. Your firm sent a Customer Notification for this issue on 6\u002F28\u002F2023. This action meets the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>b. On or about 10\u002F15\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Male-Female Midsection 40MM, due to taper post misalignment, which can result in extended surgery time or improperly assembled devices leading to future disassociation. Your firm sent a Customer Notification for this issue dated 9\u002F20\u002F2024. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>c. On or about 1\u002F22\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Collar Stem, Cemented, Fluted 13MM X 120MM and Collar Stem, Cemented, Fluted 15MM X 120MM due to mislabeling of the devices, which can result in implantation or attempted implantation of an incorrect stem size, potentially extending surgery time or causing the patient to need revision surgery. Your firm sent a Customer Notification for this issue on 12\u002F22\u002F2023. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response, dated 5\u002F14\u002F2025, regarding Observation 5 cannot be determined because we do not have assurance that your firm will make appropriate decisions following 21 CFR 806 in the future, based on your firm’s root cause stating that your firm’s SOP is ambiguous and subjective. Your firm adequately reported by retroactively submitting Reports of Correction or Removal to FDA addressing each of the three issues on 4\u002F25\u002F2025.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 712573” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Len Tokish\u003Cbr>VP of Quality Assurance &amp; Regulatory Affairs\u003Cbr>ltokish@onkossurgical.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPatrick J. Treacy\n\nRecipient Title\n\nPresident and CEO\n\nOnkos Surgical, Inc.\n\n77 E Halsey Rd\n\nParsippany, NJ 07054\n\nUnited States\n\nptreacy@onkossurgical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 712573\nJuly 21, 2025\nDear Mr. Patrick J. Treacy:\nDuring an inspection of your firm located in Parsippany, NJ from February 4, 2025 through April 4, 2025, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer of the ELEOS Limb Salvage System indicated for use in total hip and knee arthroplasty for reduction or relief of pain and\u002For improved hip function in skeletally mature patients with select conditions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Len Tokish, Vice President of Quality Assurance and Regulatory Affairs dated May 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50.\nSpecifically, you failed to adequately implement the “Approved Supplier List” section of your “Supplier, Purchasing and Inspection Controls” procedure (SOP-013; Rev. 0-6; Effective: 4\u002F25\u002F16 - 2\u002F3\u002F25) which requires that you “ensure compliance to ISO 13485” for your Tier 1 suppliers as a “method of control” over approved suppliers. For example, you did not ensure compliance to the process validation requirements (clause 7.5.6) of ISO 13485 (Medical Devices – Quality Management Systems – Requirements for regulatory purposes) for the following three (3) Tier 1 suppliers in that you failed to adequately assess and\u002For document an assessment of the acceptability of their cleaning validations meant to demonstrate that in-process or final cleaning of your ELEOS Implant Devices and Instruments consistently meet your specifications for cleanliness:\na. (b)(4) – Tier (b)(4) Final Cleaner of ELEOS Implant Devices\ni. You approved the (b)(4) cleaning validation test report TR-2771D-01 (Rev. 1-2; Approved: 1\u002F24\u002F19 and 9\u002F10\u002F21) from this supplier despite it failing to define the maximum allowable devices per gallon per run, as required by section 9.2 of the corresponding test protocol TP-2771D-01 (Rev. 2; Approved: 9\u002F10\u002F21) which states “***The main cleaning parameters that can impact the efficacy of the cleaning process include ***Quantity of parts ((b)(4))***.”\nSimilarly, you approved (b)(4) cleaning validation test report TR-2771E-01 (Rev. 1; Approved: 3\u002F18\u002F19) from this supplier despite it failing to document the maximum allowable quantity of (b)(4) and (b)(4) per run, as required by sections 9.3, 9.4, and 9.5 of the corresponding test protocol TP-2771E-01 (Rev. 1; Approved: 8\u002F28\u002F18) which state “***To validate the cleaning process, parts shall be cleaned using (b)(4) over (b)(4) runs***To create a (b)(4) batch of product***Clean what is expected to be a “(b)(4)” load in (b)(4)***A cleaning process should not alter the appearance of parts or cause damage. If applicable, appropriate fixtures to hold the components during cleaning should be included in the study and used in routine production***.”\nii. You failed to adequately assess differences in product design and geometrical configurations of candidate devices for the adoption into device families of existing (b)(4) cleaning validations conducted by this supplier because you did not accurately answer guiding questions contained in your “Assessment of Product Change or New Product Adoption for Cleaning Processes” reports. For example:\n The AC-2772-01 (Rev. 01; Effective: 7\u002F25\u002F19) and AC-277D-01 (Rev. 2; Effective: 2\u002F26\u002F21) reports show that you failed to document rationale to support your answers of “no” to the question posed in section 2 – “In relation to the existing product, does the candidate product have a similar or less complex design?” – despite the candidate devices having 4 grooves, a drive, or a male thread compared to the worst-case and comparison devices, which have none of these features.\n The AC-2772-02 report (Rev. 1; Effective: 3\u002F23\u002F20) shows that you incorrectly answered “no” to the question posed in section 2 – “In relation to the existing product, does the candidate product have fewer\u002Fsmaller or equivalent cannulated portions or lumens?” – when you compared the candidate device (segmental proximal femur, PF-2000L-02M), which has 7 cannulated holes, to the (b)(4) device ((b)(4)) and comparison devices ((b)(4)), which contain no holes.\nb. (b)(4) – Tier 1 (b)(4) Cleaner of ELEOS Implant Devices\nAlthough requested during the inspection, your Vice President of Quality Affairs and Regulatory Affairs was unable to provide documentation that you assessed the adequacy of the cleaning validations conducted in 2009 by this supplier, (b)(4). In reviewing the “Process Validation of***(b)(4) Clean Line” Operational Qualification (OQ) (E118-2116; Rev. 1; Approved: 1\u002F9\u002F09) and Performance Qualification (PQ) (E118-2116; Rev. 1; Approved: 2\u002F3\u002F09), the following deficiencies were observed:\ni. The rationale in the PQ report to accept deviations from the nominal operating range of (b)(4)°F ((b)(4), and (b)(4)°F) because OQ data showed that the process monitoring, total organic carbon (TOC), and gravimetric produced acceptable results at worst-case conditions for temperatures as low as (b)(4)°F and control charts indicated a lower control limit of (b)(4)°F (Deviation 3) does not take into account the vast differences in sample sizes ((b)(4) vs. (b)(4)) and acceptance criterion (Ppk (b)(4) vs. Ppk (b)(4)) between PQ and OQ for the same tests (TOC and gravimetric analysis) such that passing results for parameters established during OQ are not transferrable to PQ.\nii. This supplier failed to document rationale in the OQ and PQ reports for why it was acceptable to convert all negative values measured for the corrected “mass recovered from gravimetric (b)(4) and corrected “mass recovered from (b)(4) to 0.00 mg in the “Gravimetric Extraction Summary” table during gravimetric testing, thereby passing the acceptance criteria of (b)(4) mg\u002Fcm2 ((b)(4)). For example, during OQ, an (b)(4) value as high as -1.59 mg for “Hip – 4” was converted to 0.00 mg without an explanation that accounts for the possibility of testing errors, inadequate test methodology (e.g., lack of sensitivity of testing methods), and uncalibrated state of measuring equipment.\nc. (b)(4) – (b)(4) Cleaner of ELEOS Implant Devices & (b)(4) Cleaner of ELEOS Instruments\nYou approved the adoption of new products into this supplier’s existing (b)(4) cleaning validations titled “(b)(4) Cleaning Equipment & Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) and “Zenith Final Ultrasonic Cleaning Equipment & Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) per your Cleaning, Assembly, Packaging and Sterility (CAPS) Checklists for Project # 16-001 (Approved 10\u002F2\u002F24) and Project # 16-003 (Approved 4\u002F19\u002F24) referencing memo “(b)(4) Cleaning” (2\u002F14\u002F19) and results of a 3rd party audit conducted 2\u002F23\u002F18 despite the following deficiencies:\ni. The OQ and PQ protocols failed to require documentation of the load configurations for all work orders in that the Vice President of Quality Affairs and Regulatory Affairs was not able to determine if devices were put in a (b)(4) or broken up into (b)(4).\nii. The PQ protocol failed to include documentation of valid statistical rationale for cytotoxicity, endotoxin, and\u002For particulate testing. For example, the quantity tested per work order (66672, 66921, 66922) for cytotoxicity and endotoxin was (b)(4) and (b)(4) respectively and the quantity tested per work order (66675, 66919, 66920) for cytotoxicity, endotoxin, and particulate was (b)(4) and (b)(4), respectively.\nWe reviewed your firm’s response and concluded that it is not adequate. The immediate correction is to impose heightened controls at each supplier commensurate with risk until new worst-case cleaning validations can be completed that addresses each of the observed deficiencies for (b)(4) by 1\u002F15\u002F26, (b)(4) (target date not provided), and (b)(4) by 3\u002F1\u002F26 at the latest.\nFor (b)(4), an assessment of worst-case part justification by family was completed to establish new limits placed on (b)(4), and (b)(4). You plan to add this new loading criteria to the final DHR review by 7\u002F15\u002F25. In addition, you plan to require an update to (b)(4) internal procedure to include predicate cleaning validation review by 7\u002F15\u002F25. Based on the results of the new cleaning validation, you plan to revise top level procedures by (b)(4).\nFor (b)(4), an assessment of worst-case part justification was conducted and monitoring was put in place to control product release by assessing endotoxicity and cytotoxicity on a (b)(4) basis. In addition, you plan to require an update to this supplier’s internal procedures to improve notification of triggers to their customers by 7\u002F1\u002F25.\nFor (b)(4), you plan to conduct an assessment for worst-case part challenge per part family by (b)(4). For all instruments, interim clean line controls were implemented to require shipment of instruments to your firm and analyses of those instruments, which includes worst-case part and part family assessments prior to adoption into your clean-line part family. All parts successfully assessed will then be cleaned using your validated clean line prior to release for commercial distribution. All implants will continue to be shipped to (b)(4) for (b)(4) cleaning and will fall under controls established for therein.\nCorrective actions include updating your supplier control and design control procedures to establish minimum requirements for cleaning validations of implants and instruments, including defining key product attributes to consider when forming product families and what considerations trigger a new worst-case within a product family or new product cleaning family; creation of a procedure for part families and worst-case parts per family which defines and evaluates implant and instrument cleaning families to facilitate consistent assessment of device cleaning families across products; determination and justification of minimum sample size and attributes ((b)(4)) for validations; development of a cleaning validation checklist and modification of a supplier audit checklist that captures the aforementioned worst-case part determination, sample sizes, and minimum attributes that will be used during supplier assessment as part of design transfer and new supplier onboarding, manufacturing transfer, and supplier audit; and periodic review of validations on a scheduled interval against new standards and requirements by 6\u002F15\u002F25.\nHowever, no target date was provided for the new cleaning validation planned for (b)(4). Therefore, please provide a response regarding how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, you failed to implement your Post Market Surveillance procedure (QP-18-004; Rev. 3; Effective: 6\u002F30\u002F22) which requires opening a CAPA when the (b)(4) analysis of infection complaints “***is more than (b)(4) above the literature rate or (b)(4) are above the literature rate***” for a given procedure type. For example, you did not initiate CAPAs when the (b)(4) analysis for infection complaints exceeded the rates of (b)(4)% for the distal femur ((b)(4)); (b)(4)% for proximal femur ((b)(4) and (b)(4)); and (b)(4)% for total femur ((b)(4) and (b)(4)) established in the journal article by Henderson et. al “Failure Mode Classification for Tumor Endoprostheses: Retrospective Review of Five Institutions and a Literature Review” (Journal Bone and Joint Surgery 2011) by (b)(4).\nThe adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. Under CAPA 24-011 which was initiated on 9\u002F11\u002F24 to create a more robust methodology for trending and analyzing infection related complaints, you conducted a revised retrospective assessment of (b)(4) infection rates from (b)(4) to (b)(4) (TM-25-0002; Rev. B; Approved 5\u002F14\u002F25) based on additional literature data to support updated baseline infection rates by procedure type. As a part of the corrective action, you plan to create new work instructions with requirements to perform (b)(4) trend reporting for infections and (b)(4) or (b)(4) trend reports for all other postmarket surveillance key performance indicators (KPIs); revise management review presentation slides and quality planning, postmarket surveillance, complaint handling, and CAPA procedures; and provide training on the new procedures. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n3. Failure to adequately establish and maintain procedures for validating the device design with regards to risk analysis, as required by 21 CFR 820.30(g).\nSpecifically, you failed to implement section 5.9 of your “Risk Management Process” procedure (SOP-008; Rev. 4-5; Effective: 3\u002F22\u002F23 - 1\u002F17\u002F25) which requires postmarket re-evaluation of risk management for a medical device as well as monitoring of postmarket information “***for assurance that no unacceptable or previously unrecognized failure modes occur. In the event of such an occurrence the potential that the residual risk or its acceptability has changed and the impact on the previously implemented risk control measures shall be evaluated***.” For example, you failed to utilize the real rate of occurrence for loosening in complaints PCR 11272023-1 ((b)(4)), PCR 05132024-1 ((b)(4)), and PCR 10172024-1 ((b)(4)) calculated at 3.27%, 0.149%, and 3.1%, respectively, to evaluate the need to update the occurrence rating in the corresponding ELEOS Stem Implant Risk Table (Project # 16-001\u002F16-003; Rev. E; Approved: 4\u002F1\u002F19), which remains unchanged at (b)(4)% through (b)(4)% since April 1, 2019.\nAn update to the postmarket rate of occurrence changes the failure mode from an acceptable risk to a conditionally acceptable risk, thereby requiring an evaluation for the need for additional risk controls and assessment for the acceptability of the residual risk as required under sections 5.6 and 5.7 of SOP-008.\nThe adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. The immediate correction is to evaluate literature, sources, historical data, and\u002For engineering estimates against postmarket data and update the occurrence rates for the hazardous situations associated with the ELEOS Limb Salvage system by (b)(4) followed by a revision of the corresponding risk tables by (b)(4). As a part of the corrective action, you plan to revise SOP-008 to ensure that the methods used to create and maintain risk assessment tables are well-defined and create work instructions for conducting risk assessments utilizing postmarket information by (b)(4). Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n4. Failure to establish and maintain procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics, as required by 21 CFR 820.250(a).\nSpecifically, you failed to implement section 1.1 of your “Sample Size and Statistical Techniques” procedure (SOP-014; Rev. 2-4; Effective: 8\u002F16\u002F18 - 3\u002F22\u002F23) which “***identifies valid statistical techniques that are used to establish, control and verify the acceptability of process capability and product characteristics***” pertaining to “***inspections and other analyses of objective data***” of ELEOS Implant Devices received from (b)(4). during incoming inspections. For example, your Vice President of Quality Affairs and Regulatory Affairs acknowledged that the sampling plans of the (b)(4) sampled incoming device history records (DHRs) from this supplier were not traceable to a documented valid statistical rationale.\na. You reviewed and approved incoming DHRs for Lot # (b)(4) and Lot # (b)(4) on 11\u002F2\u002F20 and 11\u002F29\u002F21 where a sampling plan of (b)(4) was used to inspect critical features during in-process inspections for which there is no documented rationale for use of this sampling plan. For example, out of (b)(4) ELEOS Tibial Baseplate Component, Size 4 (Part # TB-2204E-01M) Implant Devices, the line profile (curve) for (b)(4) each were inspected against a specification of (b)(4) at (b)(4) for Lot # (b)(4). Similarly, out of (b)(4) ELEOS Collar, 28 Diameter, Round, Porous, HA Treated (Part # HB-2800R-03M) Implant Devices, the diameter for (b)(4) each was inspected against a specification of (b)(4) at (b)(4) for Lot # (b)(4).\nb. You reviewed and approved incoming DHRs (Lot #: (b)(4)) where sampling plans utilized an AQL (acceptable quality limit) of (b)(4) or (b)(4) to inspect features during in-process and final inspections for which there are no documented rationales for use of these sampling plans. For example, out of (b)(4) ELEOS Segmental Proximal Femur, Plasma Spray, Left 98 MM (Part # PF-2000L-02M) Implant Devices, the dimensional specification of (b)(4) was inspected at an AQL level of (b)(4) for Lot # (b)(4) during final inspection on 1\u002F23\u002F24.\nWe reviewed your firm’s response and concluded that it is not adequate. The immediate corrections are to use a checklist to reassess and document rationales for acceptability of the existing AQLs selected for all contract manufactured ELEOS part families from 1\u002F1\u002F21 to 4\u002F1\u002F25 and share the rationales with the contract manufacturers by 11\u002F21\u002F25 and update SCAR 25-01 to require the contract manufacturer to include documented evidence for all inspected dimensions and associated AQL quantities by 5\u002F14\u002F25. As a part of the corrective actions, you plan to update SOP-014 and WI-013-31 (Incoming Inspection Process) to require review of incoming inspection results, consolidation of sampling procedures, set up traceable valid statistical rationales, and confirm AQLs by 7\u002F6\u002F25; update SOP-007 (Design Control) and various design transfer, manufacturing transfer, supplier, and incoming inspection checklists to include instructions for the acceptance of a supplier’s sampling procedure with confirmation of conformance to those procedures during incoming inspection of supplier DHRs by (b)(4); and develop (b)(4) inspection requirement checklists for all suppliers with a sampling procedure traceable to a valid statistical rationale based on (b)(4) by 7\u002F18\u002F25. However, these corrections and\u002For corrective actions only address the need to have a statistically valid rationale for the use of sampling plans which follow AQL and not sampling plans which utilize inspections of select critical features for the (b)(4) devices. Therefore, please provide a response on how you plan to address the above deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\nCorrections and Removals Violation(s)\nOur inspection also revealed that your firm’s ELEOS Limb Salvage System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\n5. Failure to submit a medical device Report of Correction or Removal for an action initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR Part 806.10. For example:\na. Your firm conducted a removal of numerous part numbers and lot numbers of your ELEOS Limb Salvage System due to sterile packaging separation and damaged trays, which can result in extended surgery time or potential patient infection. Your firm sent a Customer Notification for this issue on 6\u002F28\u002F2023. This action meets the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nb. On or about 10\u002F15\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Male-Female Midsection 40MM, due to taper post misalignment, which can result in extended surgery time or improperly assembled devices leading to future disassociation. Your firm sent a Customer Notification for this issue dated 9\u002F20\u002F2024. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nc. On or about 1\u002F22\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Collar Stem, Cemented, Fluted 13MM X 120MM and Collar Stem, Cemented, Fluted 15MM X 120MM due to mislabeling of the devices, which can result in implantation or attempted implantation of an incorrect stem size, potentially extending surgery time or causing the patient to need revision surgery. Your firm sent a Customer Notification for this issue on 12\u002F22\u002F2023. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nThe adequacy of your firm’s response, dated 5\u002F14\u002F2025, regarding Observation 5 cannot be determined because we do not have assurance that your firm will make appropriate decisions following 21 CFR 806 in the future, based on your firm’s root cause stating that your firm’s SOP is ambiguous and subjective. Your firm adequately reported by retroactively submitting Reports of Correction or Removal to FDA addressing each of the three issues on 4\u002F25\u002F2025.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 712573” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Len Tokish\nVP of Quality Assurance & Regulatory Affairs\nltokish@onkossurgical.com","Onkos Surgical, Inc.","onkos-surgical-inc-712573-07212025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonkos-surgical-inc-712573-07212025","2026-10-26T08:09:38.140644+00:00","2025-07-29","712573","Medical Devices","Patrick J. Treacy","2026-08-19T16:32:45.913+00:00","VIA Electronic Mail","2025-07-21",{"id":55,"raw":56,"subject":61,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":67,"fei_number":19,"letter_url":68,"updated_at":69,"action_type":22,"case_status":70,"posted_date":71,"marcs_cms_no":72,"product_type":73,"closeout_date":74,"issuing_office":75,"recipient_name":76,"body_fetched_at":77,"delivery_method":78,"recipient_title":19,"reference_number":19,"action_taken_date":79,"medical_device_id":19,"response_letter_date":19},2281,[57,58,59,60,61,13,62,13],"\u003Ctime datetime=\"2022-12-27T14:20:00Z\">12\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-22T05:00:00Z\">11\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmd-pharmaceutical-supply-llc-637815-11222022\">MD Pharmaceutical Supply, LLC\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I ","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmd-pharmaceutical-supply-llc-637815-04132026\">\u003Ctime datetime=\"2026-04-17T04:00:00Z\">04\u002F17\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Richard J. Romeo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MD Pharmaceutical Supply, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>P.O. Box 244\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hanover\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>17331-2921\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 22, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Romeo:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug repackaging and relabeling facility, MD Pharmaceutical Supply, LLC at 210 Poplar Street, Suite B, Hanover, PA from April 25 to May 9, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your May 25, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to adequately investigate and document complaints or any unexplained discrepancies with the original API manufacturer.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm did not adequately investigate customer complaints for returned API. For example, you were made aware by \u003Cstrong>(b)(4)\u003C\u002Fstrong> that phentolamine mesylate API lot#&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> was returned to your facility for “quality issues.” Nonetheless, you redistributed the same lot of API to a different customer without performing an adequate investigation to assess drug quality. Additionally, records collected during the inspection indicated that 19 days after the redistribution of the same API lot, your supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, instructed you to destroy the remainder of the API lot that remained in your inventory.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA investigators observed a certificate of analysis (COA) for aminocaproic acid API lot#&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> with an expiration date of April 19, 2024, that \u003Cstrong>(b)(4)\u003C\u002Fstrong> provided you for distribution. At the request of FDA investigators, you contacted \u003Cstrong>(b)(4)\u003C\u002Fstrong> for a copy of the COA for aminocaproic acid API lot# \u003Cstrong>(b)(4)\u003C\u002Fstrong> you distributed. \u003Cstrong>(b)(4)\u003C\u002Fstrong> provided you with a COA with a different expiration date of April 19, 2023. You received COAs with disparate expiration dates for aminocaproic acid API lot# \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not initiate an investigation to assess whether the change in the expiration date was accurate and appropriate and whether the API lot you distributed with a year longer expiration date was scientifically justified.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you have established a procedure, \u003Cem>SOP MD#3-Returned goods\u003C\u002Fem>, for handling returned goods.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide a retrospective review of your distribution operations, including product quality issues identified by your supplier to assess if other API are impacted. Your newly established procedure does not include storage condition verification for API that is returned to your inventory and redistributed. It is your responsibility to ensure that API returned to your inventory and redistributed has the identity, strength, quality, and purity that it is purported to have.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective actions and preventive actions (CAPA) effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>Your action plan to address any product quality or patient safety risks for API you placed in U.S. distribution, including complaints, customer notifications, returns, recalls, and market withdraws.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Failure to perform holding of API under appropriate CGMP to avoid loss of API identity or purity.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not adequately monitor your API storage conditions. For example, the temperature probes you used to monitor your controlled substances storage area and refrigerator were not operational at the time of FDA inspection. In addition, you did not monitor your storage areas for humidity. You were unable to provide records for temperature and humidity monitoring to demonstrate that your facility held API under appropriate storage conditions that comply with manufacturers’ temperature and humidity storage requirements.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you have established a procedure, \u003Cem>SOP MD#5-Temperature and Humidity Controls\u003C\u002Fem>, for temperature and humidity monitoring.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide information on how the probe locations you select to monitor temperature and humidly are representative of the worst-case environmental conditions of your storage areas. In addition, your procedure does not identify those responsible for performing the storage condition monitoring, and how the data will be controlled, maintained, and reviewed.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment of your storage, holding, and environmental monitoring controls. Include all CAPA to be implemented, including but not limited to procedures and equipment maintenance.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your repackaging and relabeling operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Failure to perform repackaging and relabeling of API under appropriate CGMP to avoid mix-ups and potential cross-contamination.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm performed repacking and relabeling operations of API in an uncontrolled and open environment without adequate controls to prevent mix-ups and cross-contamination. For example, you relabeled Dasatinib monohydrate API and repackaged sirolimus API without label issuance, line clearance procedures, and documentation such as a batch record. Dasatinib monohydrate API is classified as highly potent and a toxic antineoplastic agent and sirolimus API is classified as an immunosuppressive agent. Both require appropriate handling and controls to prevent cross-contamination into other drugs. The drugs distributed by your firm were at risk for contamination and other hazards to drug safety because you failed to appropriately design your facility, establish effective procedures, maintain records of your activities, and implement robust controls.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you will no longer perform repacking and relabeling operations.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide a retrospective assessment to ensure that no API distribution mix-ups or cross-contamination occurred.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment of your distribution operation (e.g., shipping documents, emails correspondence with suppliers), including but not limited to reconciliation of all API received with API distributed to identify occurrence of label mix-ups.\u003C\u002Fli>\n\t\u003Cli>Your action plan to address API mix-up occurrences or potential cross-contamination identified during your retrospective review, including supplier and customer notifications and recalls. Include all associated procedures and dates for corrective actions.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the deviations we identified at your firm, we strongly recommend engaging a consultant, qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Repackaging\u002FRelabeling Cease\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease repackaging and relabeling of drugs at this facility. In response to this letter, clarify whether you intend to resume repackaging and relabeling operations of drugs at this facility in the future. If you plan to resume repackaging and relabeling operations of drugs, notify this office prior to resuming these activities.\u003C\u002Fp>\n\n\u003Cp>In addition, if you decide to transfer your ownership, contract out any processes, or move to a new location, notify this office prior to resuming your operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The deviations cited in this letter are not intended as an all-inclusive list of deviations. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\n\n\u003Cp>Correct any deviations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any and deviations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days (i.e. 12\u002F15\u002F2022). Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to orapharm1_responses@fda.hhs.gov. Please identify your response and electronic correspondence with: \u003Cstrong>MD Pharmaceuticals Supply FEI # 3012369470, Case# 637815\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, contact Compliance Officer, Juan Jimenez, at juan.jimenez@fda.hhs.gov; 973-832-9409.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nNerizza Guerin\u003Cbr>\nActing Program Division Director\u002FDistrict Director\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOPQO Division I \u002F New Jersey District\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nEmail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Richard J. Romeo\n\nRecipient Title\n\nOwner and President\n\nMD Pharmaceutical Supply, LLC\n\nP.O. Box 244\n\nHanover, PA 17331-2921\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter\n\nNovember 22, 2022\n\nDear Mr. Romeo:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug repackaging and relabeling facility, MD Pharmaceutical Supply, LLC at 210 Poplar Street, Suite B, Hanover, PA from April 25 to May 9, 2022.\n\nThis warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your May 25, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific deviations including, but not limited to, the following.\n\n1. Failure to adequately investigate and document complaints or any unexplained discrepancies with the original API manufacturer.\n\nYour firm did not adequately investigate customer complaints for returned API. For example, you were made aware by (b)(4) that phentolamine mesylate API lot# (b)(4) was returned to your facility for “quality issues.” Nonetheless, you redistributed the same lot of API to a different customer without performing an adequate investigation to assess drug quality. Additionally, records collected during the inspection indicated that 19 days after the redistribution of the same API lot, your supplier, (b)(4), instructed you to destroy the remainder of the API lot that remained in your inventory.\n\nIn addition, FDA investigators observed a certificate of analysis (COA) for aminocaproic acid API lot# (b)(4) with an expiration date of April 19, 2024, that (b)(4) provided you for distribution. At the request of FDA investigators, you contacted (b)(4) for a copy of the COA for aminocaproic acid API lot# (b)(4) you distributed. (b)(4) provided you with a COA with a different expiration date of April 19, 2023. You received COAs with disparate expiration dates for aminocaproic acid API lot# (b)(4). However, you did not initiate an investigation to assess whether the change in the expiration date was accurate and appropriate and whether the API lot you distributed with a year longer expiration date was scientifically justified.\n\nIn your response, you stated that you have established a procedure, SOP MD#3-Returned goods, for handling returned goods.\n\nYour response is inadequate. You did not provide a retrospective review of your distribution operations, including product quality issues identified by your supplier to assess if other API are impacted. Your newly established procedure does not include storage condition verification for API that is returned to your inventory and redistributed. It is your responsibility to ensure that API returned to your inventory and redistributed has the identity, strength, quality, and purity that it is purported to have.\n\nIn response to this letter, provide:\n\nA comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective actions and preventive actions (CAPA) effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nYour action plan to address any product quality or patient safety risks for API you placed in U.S. distribution, including complaints, customer notifications, returns, recalls, and market withdraws.\n\n2. Failure to perform holding of API under appropriate CGMP to avoid loss of API identity or purity.\n\nYou did not adequately monitor your API storage conditions. For example, the temperature probes you used to monitor your controlled substances storage area and refrigerator were not operational at the time of FDA inspection. In addition, you did not monitor your storage areas for humidity. You were unable to provide records for temperature and humidity monitoring to demonstrate that your facility held API under appropriate storage conditions that comply with manufacturers’ temperature and humidity storage requirements.\n\nIn your response, you stated that you have established a procedure, SOP MD#5-Temperature and Humidity Controls, for temperature and humidity monitoring.\n\nYour response is inadequate. You did not provide information on how the probe locations you select to monitor temperature and humidly are representative of the worst-case environmental conditions of your storage areas. In addition, your procedure does not identify those responsible for performing the storage condition monitoring, and how the data will be controlled, maintained, and reviewed.\n\nIn response to this letter, provide:\n\nA comprehensive assessment of your storage, holding, and environmental monitoring controls. Include all CAPA to be implemented, including but not limited to procedures and equipment maintenance.\n\nA complete assessment of documentation systems used throughout your repackaging and relabeling operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n3. Failure to perform repackaging and relabeling of API under appropriate CGMP to avoid mix-ups and potential cross-contamination.\n\nYour firm performed repacking and relabeling operations of API in an uncontrolled and open environment without adequate controls to prevent mix-ups and cross-contamination. For example, you relabeled Dasatinib monohydrate API and repackaged sirolimus API without label issuance, line clearance procedures, and documentation such as a batch record. Dasatinib monohydrate API is classified as highly potent and a toxic antineoplastic agent and sirolimus API is classified as an immunosuppressive agent. Both require appropriate handling and controls to prevent cross-contamination into other drugs. The drugs distributed by your firm were at risk for contamination and other hazards to drug safety because you failed to appropriately design your facility, establish effective procedures, maintain records of your activities, and implement robust controls.\n\nIn your response, you stated that you will no longer perform repacking and relabeling operations.\n\nYour response is inadequate. You did not provide a retrospective assessment to ensure that no API distribution mix-ups or cross-contamination occurred.\n\nIn response to this letter, provide:\n\nA comprehensive assessment of your distribution operation (e.g., shipping documents, emails correspondence with suppliers), including but not limited to reconciliation of all API received with API distributed to identify occurrence of label mix-ups.\n\nYour action plan to address API mix-up occurrences or potential cross-contamination identified during your retrospective review, including supplier and customer notifications and recalls. Include all associated procedures and dates for corrective actions.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the deviations we identified at your firm, we strongly recommend engaging a consultant, qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance\n\nDrug Repackaging\u002FRelabeling Cease\n\nWe acknowledge your commitment to cease repackaging and relabeling of drugs at this facility. In response to this letter, clarify whether you intend to resume repackaging and relabeling operations of drugs at this facility in the future. If you plan to resume repackaging and relabeling operations of drugs, notify this office prior to resuming these activities.\n\nIn addition, if you decide to transfer your ownership, contract out any processes, or move to a new location, notify this office prior to resuming your operations.\n\nConclusion\n\nThe deviations cited in this letter are not intended as an all-inclusive list of deviations. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\n\nCorrect any deviations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any and deviations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days (i.e. 12\u002F15\u002F2022). Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic response to orapharm1_responses@fda.hhs.gov. Please identify your response and electronic correspondence with: MD Pharmaceuticals Supply FEI # 3012369470, Case# 637815.\n\nIf you have any questions, contact Compliance Officer, Juan Jimenez, at juan.jimenez@fda.hhs.gov; 973-832-9409.\n\nSincerely,\n\n\u002FS\u002F\n\nNerizza Guerin\n\nActing Program Division Director\u002FDistrict Director\n\nU.S. Food and Drug Administration\n\nOPQO Division I \u002F New Jersey District\n\nCc:(b)(4)","MD Pharmaceutical Supply, LLC","md-pharmaceutical-supply-llc-637815-11222022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmd-pharmaceutical-supply-llc-637815-11222022","2026-10-26T08:09:22.322808+00:00","Closed Out","2022-12-27","637815","Drugs","2026-04-17","Division of Pharmaceutical Quality Operations I","Mr. Richard J. Romeo","2026-08-20T01:20:59.23+00:00","Email","2022-11-22",{"id":81,"raw":82,"subject":87,"body_html":88,"body_text":89,"firm_name":90,"letter_id":91,"created_at":18,"fei_number":19,"letter_url":92,"updated_at":93,"action_type":22,"case_status":23,"posted_date":94,"marcs_cms_no":95,"product_type":96,"closeout_date":19,"issuing_office":86,"recipient_name":97,"body_fetched_at":98,"delivery_method":99,"recipient_title":19,"reference_number":19,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},1974,[83,84,85,86,87,13,13,13],"\u003Ctime datetime=\"2023-07-27T13:50:00Z\">07\u002F27\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-27T04:00:00Z\">07\u002F27\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fec-supply-inc-662038-07272023\">EC Supply, Inc.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wayne W. Chang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CFO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>EC Supply, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13453 Brooks Drive, Suite A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Baldwin Park\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91706\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:wayne@ECsupplyinc.com\"> wayne@ECsupplyinc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chang:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that EC Supply, Inc. distributes Electronic Nicotine Delivery Systems (ENDS) products for commercial distribution in the United States, and that the ENDS products are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you sell and\u002For distribute to customers in the United States ENDS products that lack a marketing authorization order, including: EB Design BC5000 Disposable Pod Device Blue Razz Ice 50 mg\u002Fml and Pastel Cartel Esco Bars Mesh Watermelon Ice 5% 50mg\u002Fml 2500 puffs.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&amp;C Act (21 U.S.C. § 331(a)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300883, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nWayne W. Chang\n\nRecipient Title\n\nCFO\n\nEC Supply, Inc.\n\n13453 Brooks Drive, Suite A\n\nBaldwin Park, CA 91706\n\nUnited States\n\nwayne@ECsupplyinc.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Mr. Chang:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that EC Supply, Inc. distributes Electronic Nicotine Delivery Systems (ENDS) products for commercial distribution in the United States, and that the ENDS products are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you sell and\u002For distribute to customers in the United States ENDS products that lack a marketing authorization order, including: EB Design BC5000 Disposable Pod Device Blue Razz Ice 50 mg\u002Fml and Pastel Cartel Esco Bars Mesh Watermelon Ice 5% 50mg\u002Fml 2500 puffs.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&C Act (21 U.S.C. § 331(a)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300883, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","EC Supply, Inc.","ec-supply-inc-662038-07272023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fec-supply-inc-662038-07272023","2026-10-26T08:08:30.499826+00:00","2023-07-27","662038","Tobacco","Wayne W. Chang","2026-08-20T00:50:54.502+00:00","VIA UPS and Electronic Mail",{"id":101,"raw":102,"subject":107,"body_html":109,"body_text":110,"firm_name":111,"letter_id":112,"created_at":113,"fei_number":19,"letter_url":114,"updated_at":115,"action_type":22,"case_status":70,"posted_date":116,"marcs_cms_no":117,"product_type":118,"closeout_date":119,"issuing_office":106,"recipient_name":120,"body_fetched_at":121,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":122,"medical_device_id":19,"response_letter_date":19},3272,[103,104,105,106,107,13,108,13],"\u003Ctime datetime=\"2021-07-06T13:20:00Z\">07\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-25T04:00:00Z\">06\u002F25\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdavati-medical-supply-llc-615530-06252021\">Davati Medical Supply LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research","Unapproved and Misbranded Product Related to Influenza Virus","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdavati-medical-supply-llc-615530-10142021\">\u003Ctime datetime=\"2021-10-14T04:00:00Z\">10\u002F14\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Herman Cardenas\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Davati Medical Supply LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3121 Eagles Nest St., Suite 120\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Round Rock\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78665\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:contact@davatimedical.com\"> contact@davatimedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>CBER 21-02\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: June 25, 2021\u003Cbr>\n\u003Cbr>\nRE: Unapproved and Misbranded Product Related to Influenza Virus\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at www.davatimedical.com, on June 22, 2021. Your website directs consumers to contact you to purchase FLUZALP® QUADRIVALENT, Influenza Vaccine, which you represent is manufactured by Anzalp Pharmasolutions Pvt. Ltd. The FDA has observed that you offer this influenza vaccine product for sale in the United States and that the product is intended to mitigate, prevent, treat, diagnose, or cure Influenza Virus, commonly referred to as “the Flu”, in people.\u003C\u002Fp>\n\n\u003Cp>Based on our review, this product is an unapproved new drug under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355. Furthermore, this product is a misbranded drug under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>Your product is also an unlicensed biological product under section 351 of the Public Health Service Act (PHS Act), 42 U.S.C. § 262. In order to lawfully market a drug that is also a biological product, a valid biologics license must be in effect under the PHS Act. 42 U.S.C. § 262(a). Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations. 21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312. Your product is not the subject of an approved biologics license application (BLA) nor is there an IND in effect for your product.\u003C\u002Fp>\n\n\u003Cp>FDA is taking urgent measures to protect consumers from certain products that, without licensure, approval, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure Influenza Virus in people. As described in this letter, you offer for sale a product that is intended to mitigate, prevent, treat, diagnose, or cure Influenza Virus in people. We request that you take immediate action to cease the sale of any unlicensed, unapproved, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of Influenza Virus.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website that establish the intended use of your product and misleadingly represent it as safe and\u002For effective for the prevention of Influenza Virus include:\u003C\u002Fp>\n\n\u003Cp>• “FLUZALP™ Quadrivalent is an inactivated Influenza vaccine indicated for active immunization against Influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUZALP QUADRIVALENT is approved for use in persons 4 years of age and older.”\u003C\u002Fp>\n\n\u003Cp>• “The quadruple strain formula provides protection for up to 6 months*. The product’s dosage form is injection, suspension and is administered via intramuscular form.”\u003C\u002Fp>\n\n\u003Cp>• “Each batch of these vaccines is then tested by FDA for Quantity, Quality and Efficacy before being release [sic] into the market.”\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to correct any violations of the FD&amp;C Act, the PHS Act, and FDA’s implementing regulations. This letter is not meant to be an all-inclusive list of violations that exist in connection with your product or operations. It is your responsibility to ensure that you and your products fully comply with the law.\u003C\u002Fp>\n\n\u003Cp>We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product as safe and effective for an Influenza Virus-related use for which it has not been licensed by FDA and that you do not make claims that misbrand the product in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to CBERDCMRecommendations@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which your product is exported to the United States that FDA considers your product referenced above to be an unapproved and misbranded product that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Mary A. Malarkey\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nHerman Cardenas\n\nDavati Medical Supply LLC\n\n3121 Eagles Nest St., Suite 120\n\nRound Rock, TX 78665\n\nUnited States\n\ncontact@davatimedical.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nCBER 21-02\n\nWARNING LETTER\n\nDate: June 25, 2021\n\nRE: Unapproved and Misbranded Product Related to Influenza Virus\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at www.davatimedical.com, on June 22, 2021. Your website directs consumers to contact you to purchase FLUZALP® QUADRIVALENT, Influenza Vaccine, which you represent is manufactured by Anzalp Pharmasolutions Pvt. Ltd. The FDA has observed that you offer this influenza vaccine product for sale in the United States and that the product is intended to mitigate, prevent, treat, diagnose, or cure Influenza Virus, commonly referred to as “the Flu”, in people.\n\nBased on our review, this product is an unapproved new drug under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355. Furthermore, this product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nYour product is also an unlicensed biological product under section 351 of the Public Health Service Act (PHS Act), 42 U.S.C. § 262. In order to lawfully market a drug that is also a biological product, a valid biologics license must be in effect under the PHS Act. 42 U.S.C. § 262(a). Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations. 21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312. Your product is not the subject of an approved biologics license application (BLA) nor is there an IND in effect for your product.\n\nFDA is taking urgent measures to protect consumers from certain products that, without licensure, approval, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure Influenza Virus in people. As described in this letter, you offer for sale a product that is intended to mitigate, prevent, treat, diagnose, or cure Influenza Virus in people. We request that you take immediate action to cease the sale of any unlicensed, unapproved, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of Influenza Virus.\n\nSome examples of the claims on your website that establish the intended use of your product and misleadingly represent it as safe and\u002For effective for the prevention of Influenza Virus include:\n\n• “FLUZALP™ Quadrivalent is an inactivated Influenza vaccine indicated for active immunization against Influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUZALP QUADRIVALENT is approved for use in persons 4 years of age and older.”\n\n• “The quadruple strain formula provides protection for up to 6 months*. The product’s dosage form is injection, suspension and is administered via intramuscular form.”\n\n• “Each batch of these vaccines is then tested by FDA for Quantity, Quality and Efficacy before being release [sic] into the market.”\n\nYou should take immediate action to correct any violations of the FD&C Act, the PHS Act, and FDA’s implementing regulations. This letter is not meant to be an all-inclusive list of violations that exist in connection with your product or operations. It is your responsibility to ensure that you and your products fully comply with the law.\n\nWe advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product as safe and effective for an Influenza Virus-related use for which it has not been licensed by FDA and that you do not make claims that misbrand the product in violation of the FD&C Act. Within 48 hours, please send an email to CBERDCMRecommendations@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which your product is exported to the United States that FDA considers your product referenced above to be an unapproved and misbranded product that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at CBERDCMRecommendations@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMary A. Malarkey\n\nDirector\n\nOffice of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\nU.S. Food and Drug Administration","Davati Medical Supply LLC","davati-medical-supply-llc-615530-06252021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdavati-medical-supply-llc-615530-06252021","2026-10-26T08:08:21.596641+00:00","2021-07-06","615530","Biologics","2021-10-14","Herman Cardenas","2026-08-20T02:59:22.938+00:00","2021-06-25",{"id":124,"raw":125,"subject":130,"body_html":131,"body_text":132,"firm_name":133,"letter_id":134,"created_at":18,"fei_number":19,"letter_url":135,"updated_at":136,"action_type":22,"case_status":23,"posted_date":137,"marcs_cms_no":138,"product_type":73,"closeout_date":19,"issuing_office":129,"recipient_name":139,"body_fetched_at":140,"delivery_method":141,"recipient_title":19,"reference_number":19,"action_taken_date":142,"medical_device_id":19,"response_letter_date":19},1610,[126,127,128,129,130,13,13,13],"\u003Ctime datetime=\"2024-02-13T14:20:00Z\">02\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-07T05:00:00Z\">02\u002F07\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynthetix-inc-dba-helix-chemical-supply-668918-02072024\">Synthetix Inc. DBA Helix Chemical Supply\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Matthew Lucks\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Synthetix Inc. DBA Helix Chemical Supply\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>558 Grand Concourse Suite 279\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bronx\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10451\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@helixchem.co\"> info@helixchem.co\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 7, 2024\u003C\u002Fp>\n\n\u003Cp>RE: 668918\u003C\u002Fp>\n\n\u003Cp>Dear Matthew Lucks:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.helixchem.com in October 2023 and has observed that your website offers “Semaglutide” and “Tirzepatide” products for sale in the United States. As described below, your “Semaglutide” and “Tirzepatide” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 301(d). Furthermore, your “Semaglutide” and “Tirzepatide” products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. 352, introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Despite statements on your product labeling marketing your products for “research use only” and “not for human consumption,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims from the products’ labeling, including as observed on your website that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>From your website www.helixchem.com:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Semaglutide\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Dose Amounts\u003Cbr>\nEach vial contains:\u003Cbr>\nWeeks 1-4 – 8 doses (reconstituted vial expires after 8 weeks.)\u003Cbr>\nWeeks 5-8 – 8 doses (reconstituted vial expires after 8 weeks.) . . .\u003Cbr>\nSemaglutide is a derivative of the naturally occurring GLP-1, a peptide known to lower blood sugar levels and enhance insulin secretion. Research shows that Semaglutide may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Tirzepatide\u003C\u002Fstrong>\u003Cbr>\n“Dose Amounts\u003Cbr>\nEach vial contains:\u003Cbr>\nWeeks 1-4 – 4 doses\u003Cbr>\nWeeks 5-8 – 2 doses. . .\u003Cbr>\nTirzepatide is a synthetic derivative of gastric inhibitory polypeptide (GIP) that has simultaneous glucagon-like peptide-1 (GLP-1) functionality.”\u003C\u002Fp>\n\n\u003Cp>From the “Standard Dose Protocol for Tirzepatide Research” document accompanying Tirzepatide:\u003C\u002Fp>\n\n\u003Cp>“If additional glycemic control is needed. . . This is the standard schedule for the medication, Mounjaro.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your “Semaglutide” and “Tirzepatide” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355 are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your “Semaglutide” and “Tirzepatide” products are also misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for their intended use(s). “Adequate directions for use” means directions under which a layman can use a drug safely and for the purposes for which it is intended, 21 C.F.R. 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, 21 U.S.C. 353(b)(1), include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Your “Semaglutide” product is indicated for a condition that is not amenable to self-diagnosis and treatment by a layperson, therefore adequate directions cannot be written such that a layperson can use the product safely for its intended use. In addition, your “Semaglutide” and “Tirzepatide” products are also prescription drugs as defined in section 503(b)(1)(A) of the FD&amp;C Act, 21 U.S.C. 353(b)(1)(A), in light of their toxicity or potential for harmful effects, methods of use, or collateral measures necessary for their use. For these reasons, your “Semaglutide” and “Tirzepatide” products are misbranded under section 502(f)(1) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>The introduction, delivery for introduction, or causing the introduction or delivery for introduction into interstate commerce of these misbranded drugs is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMatthew Lucks\n\nSynthetix Inc. DBA Helix Chemical Supply\n\n558 Grand Concourse Suite 279\n\nBronx, NY 10451\n\nUnited States\n\ninfo@helixchem.co\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nFebruary 7, 2024\n\nRE: 668918\n\nDear Matthew Lucks:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.helixchem.com in October 2023 and has observed that your website offers “Semaglutide” and “Tirzepatide” products for sale in the United States. As described below, your “Semaglutide” and “Tirzepatide” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 301(d). Furthermore, your “Semaglutide” and “Tirzepatide” products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. 352, introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nDespite statements on your product labeling marketing your products for “research use only” and “not for human consumption,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims from the products’ labeling, including as observed on your website that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:\n\nFrom your website www.helixchem.com:\n\nSemaglutide\n\n“Dose Amounts\n\nEach vial contains:\n\nWeeks 1-4 – 8 doses (reconstituted vial expires after 8 weeks.)\n\nWeeks 5-8 – 8 doses (reconstituted vial expires after 8 weeks.) . . .\n\nSemaglutide is a derivative of the naturally occurring GLP-1, a peptide known to lower blood sugar levels and enhance insulin secretion. Research shows that Semaglutide may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease.”\n\nTirzepatide\n\n“Dose Amounts\n\nEach vial contains:\n\nWeeks 1-4 – 4 doses\n\nWeeks 5-8 – 2 doses. . .\n\nTirzepatide is a synthetic derivative of gastric inhibitory polypeptide (GIP) that has simultaneous glucagon-like peptide-1 (GLP-1) functionality.”\n\nFrom the “Standard Dose Protocol for Tirzepatide Research” document accompanying Tirzepatide:\n\n“If additional glycemic control is needed. . . This is the standard schedule for the medication, Mounjaro.”\n\nUnapproved New Drugs\n\nYour “Semaglutide” and “Tirzepatide” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nMisbranded Drugs\n\nYour “Semaglutide” and “Tirzepatide” products are also misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for their intended use(s). “Adequate directions for use” means directions under which a layman can use a drug safely and for the purposes for which it is intended, 21 C.F.R. 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. 353(b)(1), include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Your “Semaglutide” product is indicated for a condition that is not amenable to self-diagnosis and treatment by a layperson, therefore adequate directions cannot be written such that a layperson can use the product safely for its intended use. In addition, your “Semaglutide” and “Tirzepatide” products are also prescription drugs as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. 353(b)(1)(A), in light of their toxicity or potential for harmful effects, methods of use, or collateral measures necessary for their use. For these reasons, your “Semaglutide” and “Tirzepatide” products are misbranded under section 502(f)(1) of the FD&C Act.\n\nThe introduction, delivery for introduction, or causing the introduction or delivery for introduction into interstate commerce of these misbranded drugs is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration","Synthetix Inc. DBA Helix Chemical Supply","synthetix-inc-dba-helix-chemical-supply-668918-02072024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynthetix-inc-dba-helix-chemical-supply-668918-02072024","2026-10-26T08:10:09.323296+00:00","2024-02-13","668918","Matthew Lucks","2026-08-20T00:18:52.044+00:00","Via Email","2024-02-07",{"id":144,"raw":145,"subject":151,"body_html":152,"body_text":153,"firm_name":154,"letter_id":155,"created_at":156,"fei_number":19,"letter_url":157,"updated_at":158,"action_type":22,"case_status":23,"posted_date":159,"marcs_cms_no":160,"product_type":118,"closeout_date":19,"issuing_office":149,"recipient_name":161,"body_fetched_at":162,"delivery_method":163,"recipient_title":19,"reference_number":19,"action_taken_date":164,"medical_device_id":19,"response_letter_date":19},2854,[146,147,148,149,150,13,13,13],"\u003Ctime datetime=\"2022-02-22T14:20:00Z\">02\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-02T05:00:00Z\">02\u002F02\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsmart-surgical-inc-dba-burst-biologics-614361-02022022\">Smart Surgical, Inc dba Burst Biologics\u003C\u002Fa>","Office of Biological Products Operations – Division 2","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Christopher D. Jones\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Smart Surgical, Inc dba Burst Biologics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3501 W. Elder St., Ste. 104\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Boise\u003C\u002Fspan>, \u003Cspan>ID\u003C\u002Fspan> \u003Cspan>83705\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 2, 2022\u003C\u002Fp>\n\n\u003Cp>[OBPO 21-614361]\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jones:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Smart Surgical, Inc., dba Burst Biologics (hereinafter, Burst Biologics), located at 3501 W. Elder St., Ste. 104, Boise, ID 83705, conducted between February 22, 2021 and March 5, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human umbilical cord blood, namely, BioBurst Fluid and BioBurst Rejuv, for allogeneic use. You distribute your products to health care providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to and during the inspection, including information on the Burst Biologics website, burstbiologics.com, reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Burst Biologics does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FPs derived from human umbilical cord blood fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” Your umbilical cord blood derived products are not intended to perform the same basic function or functions of the umbilical cord blood in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system. Rather, your products are intended to be applied to surgical and injury sites to supplement tissue defects and for orthopedic use, and your products could be administered via intra-articular injection. Using your umbilical cord blood derived products in this manner is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>In addition, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(4) because they are manufactured from allogeneic umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function, and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\u003C\u002Fp>\n\n\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Because these HCT\u002FPs do not meet all the criteria in 21 CFR 1271.10(a), and Burst Biologics does not qualify for any exception in 21 CFR 1271.15, the products are regulated as drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your HCT\u002FPs derived from human umbilical cord blood are not the subject of an approved biologics license application (BLA) nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Part 1271. The deviations in manufacturing observed, as well as those noted in documents collected during the inspection, indicate that the use of your products raises potential significant safety concerns. For example, your deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring, as described below, pose a significant risk that your products may be contaminated with microorganisms or have other serious product quality defects.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant deviations from CGMP and CGTP requirements applicable to your products. These deficiencies include, but are not limited to, the following:\u003Cbr>\n\u003Cbr>\n\u003Cstrong>1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)].\u003C\u002Fstrong> FDA has identified Zika virus (ZIKV) as a relevant communicable disease agent or disease (RCDAD) under 21 CFR 1271.3(r)(2). Since ZIKV is a RCDAD, donors of umbilical cord, blood, placenta or other gestational tissues should be considered ineligible if certain risk factors are present. However, in May 2016, you began receiving umbilical cord blood units recovered from allogeneic donors in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an area considered at increased risk for ZIKV, and you failed to determine these donors as ineligible. These umbilical cord blood units were manufactured into BioBurst Fluid and BioBurst Rejuv and distributed throughout the United States. Although you have since developed new procedures that provide for assessing eligibility based on ZIKV, your prior deficiencies raise potentially significant safety concerns.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> Your firm failed to adequately validate the aseptic process used to manufacture BioBurst Fluid and BioBurst Rejuv (i.e., by performing media fill simulations) since manufacturing began in December 2015. Since then, your firm manufactured and distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of BioBurst Fluid and BioBurst Rejuv. These products purport to be sterile. More specifically:\u003C\u002Fp>\n\n\u003Cp>a. Prior to October 31, 2019, you did not conduct any media fill simulations to validate the aseptic manufacturing process for BioBurst Fluid and BioBurst Rejuv to demonstrate that your aseptic process can consistently produce products free of viable microorganisms.\u003C\u002Fp>\n\n\u003Cp>b. On October 31, 2019, a validation plan (VAL-PR-UCB Product Manufacturing-003) under which media fill simulations were conducted to validate your aseptic process for BioBurst Fluid and BioBurst Rejuv was approved; however, the media fills performed under this plan are inadequate\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. For example, the units produced during your media fill simulations were not incubated under conditions adequate to detect microorganisms that might otherwise be difficult to culture. Media fill samples were only incubated for \u003Cstrong>(b)(4)\u003C\u002Fstrong> days.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> Your firm has not established an adequate system for environmental, including personnel, monitoring in the aseptic processing areas where BioBurst Fluid and BioBurst Rejuv are manufactured. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm does not investigate personnel monitoring excursions that exceed your action limit. Approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of product associated with personnel monitoring excursions that were not investigated were distributed since October 2020.\u003C\u002Fp>\n\n\u003Cp>b. Your environmental monitoring procedure describes that up to and including \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>colony forming units (CFUs) is an acceptable result for a single personnel monitoring sample, including a sample from glove fingertips that enter the ISO-5 classified biological safety cabinet (BSC) where aseptic processing is conducted. We note that the current industry standard is &lt;1 CFU\u002Fplate for gloves or sleeves that enter the ISO-5 classified area and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for gowning that remains in the ISO-7 classified area. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potential significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\">https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\u003C\u002Fa>. FDA’s guidance documents do not establish legal requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to withhold from use each lot of components, drug product containers, and closures until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84(a)].\u003C\u002Fstrong> Specifically, you told our investigator that components utilized within UCB (umbilical cord blood) manufacturing are not sampled and tested prior to being used in production.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192].\u003C\u002Fstrong> Specifically, since December 2015, your firm has had numerous sterility failures for batches of BioBurst Fluid and BioBurst Rejuv that you failed to investigate to determine the source of the contamination beyond identifying organisms (for example, a \u003Cem>Paenibacillus\u003C\u002Fem> species, \u003Cem>Bacillus\u003C\u002Fem> non-anthracis, \u003Cem>Kocuria rhizophila\u003C\u002Fem>,&nbsp;\u003Cem>Staphylococcus hominis\u003C\u002Fem>, and \u003Cem>Micrococcus luteus\u003C\u002Fem>) for a subset of these failed batches. For over 80% of the failures, you did not identify the contaminating microorganism(s). Since December 2015, your firm manufactured and distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of BioBurst Fluid and BioBurst Rejuv.\u003C\u002Fp>\n\n\u003Cp>In addition to the above violations, we also note that we are concerned that you may not have verified the suitability of your sterility test method, that you represent is based on USP &lt;71&gt;, used for final product release testing of BioBurst Fluid and BioBurst Rejuv batches from December 2015 until July 31, 2020. Numerous BioBurst Fluid and BioBurst Rejuv batches remain within expiry. Please be reminded that you are required to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods employed, in accordance with 21 CFR 211.165(e).\u003Cbr>\n\u003Cbr>\nWe acknowledge receipt of your correspondences, dated April 16, 2021 and May 14, 2021, responding to FDA’s inspectional observations on the FDA-483. We have reviewed the corrective actions outlined in the response, and we have determined that the response is inadequate to address our concerns. The responses to many of the observations do not provide sufficient detail to fully assess the adequacy of your corrective actions to date, lack a timeline for completion of all necessary corrective actions, and lack documentation to demonstrate that you have corrected your violations. Additionally, your responses are unsatisfactory in that they do not address your firm’s manufacture and distribution of your products derived from umbilical cord blood under the violative conditions outlined above. Nor do your responses remedy the above-noted violations.\u003C\u002Fp>\n\n\u003Cp>While you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Amy Graf, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>cc\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>_______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We also found no indication that the media used in your media fill simulation was demonstrated to promote growth of organisms pre- or post-incubation of media-filled units. Growth promotion of each batch of media should be performed to demonstrate the media is capable of detecting microorganisms. Furthermore, the October 2019 study was the only executed media fill simulation provided to FDA during the inspection. We recommend that routine media fill simulations be conducted semi-annually to evaluate the state of control of the aseptic process.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMr. Christopher D. Jones\n\nRecipient Title\n\nChief Executive Officer\n\nSmart Surgical, Inc dba Burst Biologics\n\n3501 W. Elder St., Ste. 104\n\nBoise, ID 83705\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division 2\n\nUnited States\n\nWARNING LETTER\n\nFebruary 2, 2022\n\n[OBPO 21-614361]\n\nDear Mr. Jones:\n\nDuring an inspection of your firm, Smart Surgical, Inc., dba Burst Biologics (hereinafter, Burst Biologics), located at 3501 W. Elder St., Ste. 104, Boise, ID 83705, conducted between February 22, 2021 and March 5, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human umbilical cord blood, namely, BioBurst Fluid and BioBurst Rejuv, for allogeneic use. You distribute your products to health care providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to and during the inspection, including information on the Burst Biologics website, burstbiologics.com, reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBurst Biologics does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FPs derived from human umbilical cord blood fail to meet all the criteria in 21 CFR 1271.10(a).\n\nSpecifically, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” Your umbilical cord blood derived products are not intended to perform the same basic function or functions of the umbilical cord blood in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system. Rather, your products are intended to be applied to surgical and injury sites to supplement tissue defects and for orthopedic use, and your products could be administered via intra-articular injection. Using your umbilical cord blood derived products in this manner is not homologous use as defined in 21 CFR 1271.3(c).\n\nIn addition, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(4) because they are manufactured from allogeneic umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function, and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\n\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Because these HCT\u002FPs do not meet all the criteria in 21 CFR 1271.10(a), and Burst Biologics does not qualify for any exception in 21 CFR 1271.15, the products are regulated as drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\n\nPlease be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your HCT\u002FPs derived from human umbilical cord blood are not the subject of an approved biologics license application (BLA) nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Part 1271. The deviations in manufacturing observed, as well as those noted in documents collected during the inspection, indicate that the use of your products raises potential significant safety concerns. For example, your deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring, as described below, pose a significant risk that your products may be contaminated with microorganisms or have other serious product quality defects.\n\nAt the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant deviations from CGMP and CGTP requirements applicable to your products. These deficiencies include, but are not limited to, the following:\n\n1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)]. FDA has identified Zika virus (ZIKV) as a relevant communicable disease agent or disease (RCDAD) under 21 CFR 1271.3(r)(2). Since ZIKV is a RCDAD, donors of umbilical cord, blood, placenta or other gestational tissues should be considered ineligible if certain risk factors are present. However, in May 2016, you began receiving umbilical cord blood units recovered from allogeneic donors in (b)(4), an area considered at increased risk for ZIKV, and you failed to determine these donors as ineligible. These umbilical cord blood units were manufactured into BioBurst Fluid and BioBurst Rejuv and distributed throughout the United States. Although you have since developed new procedures that provide for assessing eligibility based on ZIKV, your prior deficiencies raise potentially significant safety concerns.\n\n2. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. Your firm failed to adequately validate the aseptic process used to manufacture BioBurst Fluid and BioBurst Rejuv (i.e., by performing media fill simulations) since manufacturing began in December 2015. Since then, your firm manufactured and distributed approximately (b)(4) units of BioBurst Fluid and BioBurst Rejuv. These products purport to be sterile. More specifically:\n\na. Prior to October 31, 2019, you did not conduct any media fill simulations to validate the aseptic manufacturing process for BioBurst Fluid and BioBurst Rejuv to demonstrate that your aseptic process can consistently produce products free of viable microorganisms.\n\nb. On October 31, 2019, a validation plan (VAL-PR-UCB Product Manufacturing-003) under which media fill simulations were conducted to validate your aseptic process for BioBurst Fluid and BioBurst Rejuv was approved; however, the media fills performed under this plan are inadequate1. For example, the units produced during your media fill simulations were not incubated under conditions adequate to detect microorganisms that might otherwise be difficult to culture. Media fill samples were only incubated for (b)(4) days.\n\n3. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)]. Your firm has not established an adequate system for environmental, including personnel, monitoring in the aseptic processing areas where BioBurst Fluid and BioBurst Rejuv are manufactured. For example:\n\na. Your firm does not investigate personnel monitoring excursions that exceed your action limit. Approximately (b)(4) units of product associated with personnel monitoring excursions that were not investigated were distributed since October 2020.\n\nb. Your environmental monitoring procedure describes that up to and including (b)(4) colony forming units (CFUs) is an acceptable result for a single personnel monitoring sample, including a sample from glove fingertips that enter the ISO-5 classified biological safety cabinet (BSC) where aseptic processing is conducted. We note that the current industry standard is \u003C1 CFU\u002Fplate for gloves or sleeves that enter the ISO-5 classified area and (b)(4) for gowning that remains in the ISO-7 classified area. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potential significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf. FDA’s guidance documents do not establish legal requirements.\n\n4. Failure to withhold from use each lot of components, drug product containers, and closures until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84(a)]. Specifically, you told our investigator that components utilized within UCB (umbilical cord blood) manufacturing are not sampled and tested prior to being used in production.\n\n5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192]. Specifically, since December 2015, your firm has had numerous sterility failures for batches of BioBurst Fluid and BioBurst Rejuv that you failed to investigate to determine the source of the contamination beyond identifying organisms (for example, a Paenibacillus species, Bacillus non-anthracis, Kocuria rhizophila, Staphylococcus hominis, and Micrococcus luteus) for a subset of these failed batches. For over 80% of the failures, you did not identify the contaminating microorganism(s). Since December 2015, your firm manufactured and distributed approximately (b)(4) units of BioBurst Fluid and BioBurst Rejuv.\n\nIn addition to the above violations, we also note that we are concerned that you may not have verified the suitability of your sterility test method, that you represent is based on USP \u003C71>, used for final product release testing of BioBurst Fluid and BioBurst Rejuv batches from December 2015 until July 31, 2020. Numerous BioBurst Fluid and BioBurst Rejuv batches remain within expiry. Please be reminded that you are required to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods employed, in accordance with 21 CFR 211.165(e).\n\nWe acknowledge receipt of your correspondences, dated April 16, 2021 and May 14, 2021, responding to FDA’s inspectional observations on the FDA-483. We have reviewed the corrective actions outlined in the response, and we have determined that the response is inadequate to address our concerns. The responses to many of the observations do not provide sufficient detail to fully assess the adequacy of your corrective actions to date, lack a timeline for completion of all necessary corrective actions, and lack documentation to demonstrate that you have corrected your violations. Additionally, your responses are unsatisfactory in that they do not address your firm’s manufacture and distribution of your products derived from umbilical cord blood under the violative conditions outlined above. Nor do your responses remedy the above-noted violations.\n\nWhile you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nNeither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Amy Graf, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\ncc\n\n(b)(6)\n\n_______________________________\n\n1 We also found no indication that the media used in your media fill simulation was demonstrated to promote growth of organisms pre- or post-incubation of media-filled units. Growth promotion of each batch of media should be performed to demonstrate the media is capable of detecting microorganisms. Furthermore, the October 2019 study was the only executed media fill simulation provided to FDA during the inspection. We recommend that routine media fill simulations be conducted semi-annually to evaluate the state of control of the aseptic process.","Smart Surgical, Inc dba Burst Biologics","smart-surgical-inc-dba-burst-biologics-614361-02022022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsmart-surgical-inc-dba-burst-biologics-614361-02022022","2026-10-26T08:09:59.293166+00:00","2022-02-22","614361","Mr. Christopher D. Jones","2026-08-20T02:09:59.584+00:00","VIA UNITED PARCEL SERVICE","2022-02-02",{"id":166,"raw":167,"subject":87,"body_html":170,"body_text":171,"firm_name":172,"letter_id":173,"created_at":174,"fei_number":19,"letter_url":175,"updated_at":176,"action_type":22,"case_status":23,"posted_date":177,"marcs_cms_no":178,"product_type":96,"closeout_date":19,"issuing_office":86,"recipient_name":179,"body_fetched_at":180,"delivery_method":99,"recipient_title":19,"reference_number":181,"action_taken_date":177,"medical_device_id":19,"response_letter_date":19},1331,[168,168,169,86,87,13,13,13],"\u003Ctime datetime=\"2024-07-31T04:00:00Z\">07\u002F31\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-supply-allies-inc-dba-vapor-grab-689151-07312024\">Global Supply Allies Inc. d\u002Fb\u002Fa Vapor Grab\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2402178\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason Lopez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Global Supply Allies Inc. d\u002Fb\u002Fa Vapor Grab\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>35 Royal Tern Ln\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Aliso Viejo\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92656\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Orders@vaporgrab.com\"> Orders@vaporgrab.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 31, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Jason Lopez:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fvaporgrab.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: Geek Bar Pulse Disposable – Frozen Cherry Apple and Geek Bar Pulse Disposable – Frozen Blackberry Fab.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402178, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>John E. Verbeten\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>1API GmbH\u003Cbr>\nabuse@1api.net\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\u003Cp>E-CIG Vault, LLC\u003Cbr>\nAttn: Jason Lopez and Garrett Mann\u003Cbr>\n27058 La Paz Rd\u003Cbr>\nAliso Viejo, CA 92656\u003C\u002Fp>\n\n\u003Cp>Global Supply Allies Inc.\u003Cbr>\nAttn: Brendon Manguso\u003Cbr>\n24352 Acaso, APT 5\u003Cbr>\nLaguna Hills, CA 92656\u003C\u002Fp>\n\n\u003Cp>California Registered Corporate Agent (1505)\u003Cbr>\nLEGALZOOM.COM, INC.\u003Cbr>\nAttn: Joyce Yi, Sandra Menjivar, Jesse Camarena, Arielle Devay\u003Cbr>\n101 N Brand Blvd 11TH FL\u003Cbr>\nGlendale, CA 91203\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2402178\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJason Lopez\n\nGlobal Supply Allies Inc. d\u002Fb\u002Fa Vapor Grab\n\n35 Royal Tern Ln\n\nAliso Viejo, CA 92656\n\nUnited States\n\nOrders@vaporgrab.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJuly 31, 2024\n\nWARNING LETTER\n\nDear Jason Lopez:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fvaporgrab.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: Geek Bar Pulse Disposable – Frozen Cherry Apple and Geek Bar Pulse Disposable – Frozen Blackberry Fab.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402178, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJohn E. Verbeten\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\n1API GmbH\n\nabuse@1api.net\n\nShopify, Inc.\n\nabuse@shopify.com\n\nE-CIG Vault, LLC\n\nAttn: Jason Lopez and Garrett Mann\n\n27058 La Paz Rd\n\nAliso Viejo, CA 92656\n\nGlobal Supply Allies Inc.\n\nAttn: Brendon Manguso\n\n24352 Acaso, APT 5\n\nLaguna Hills, CA 92656\n\nCalifornia Registered Corporate Agent (1505)\n\nLEGALZOOM.COM, INC.\n\nAttn: Joyce Yi, Sandra Menjivar, Jesse Camarena, Arielle Devay\n\n101 N Brand Blvd 11TH FL\n\nGlendale, CA 91203","Global Supply Allies Inc. d\u002Fb\u002Fa Vapor Grab","global-supply-allies-inc-dba-vapor-grab-689151-07312024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-supply-allies-inc-dba-vapor-grab-689151-07312024","2026-10-26T08:08:46.85489+00:00","2024-07-31","689151","Jason Lopez","2026-08-19T23:54:52.275+00:00","RW2402178",8,{"510k":184,"classification":185,"enforcement":186,"event":187,"event_backfill":188,"pma":189,"warning_letter":190},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]